FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2934961572> ?p ?o ?g. }

• W2934961572 abstract "Background Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on safety and efficacy of autologous CD19-targeted CAR T-cells for these patients; here we report safety and long-term follow-up of CAR T-cell therapy with or without conditioning chemotherapy for patients with R/R CLL and indolent B-cell non-Hodgkin lymphoma (B-NHL). Methods We conducted a phase 1 clinical trial investigating CD19-targeted CAR T-cells incorporating a CD28 costimulatory domain (19-28z). Seventeen of 20 patients received conditioning chemotherapy prior to CAR T-cell infusion. Five patients with CLL received ibrutinib at the time of autologous T-cell collection and/or CAR T-cell administration. Results This analysis included 16 patients with R/R CLL and 4 patients with R/R indolent B-NHL. Cytokine release syndrome (CRS) was observed in all 20 patients but grades 3 and 4 CRS and neurological events were uncommon (10% for each). Ex vivo expansion of T-cells and proportions of CD4+/CD8+ CAR T-cells with CD62L+CD127+ immunophenotype were significantly greater in patients on ibrutinib at leukapheresis. Three of 12 evaluable CLL patients receiving conditioning chemotherapy achieved CR (two had minimal residual disease-negative CR). All patients achieving CR remained progression-free at median follow-up of 53 months. Conclusion Conditioning chemotherapy and 19-28z CAR T-cells were acceptably tolerated across investigated dose levels in heavily pretreated patients with R/R CLL and indolent B-NHL, and a subgroup of patients achieved durable CR. Ibrutinib therapy may modulate autologous T-cell phenotype. Trial registration ClinicalTrials.gov NCT00466531. Funding Juno Therapeutics." @default.
• W2934961572 created "2019-04-11" @default.
• W2934961572 creator A5010957292 @default.
• W2934961572 creator A5011077747 @default.
• W2934961572 creator A5036831073 @default.
• W2934961572 creator A5040703931 @default.
• W2934961572 creator A5042888186 @default.
• W2934961572 creator A5044552886 @default.
• W2934961572 creator A5052659722 @default.
• W2934961572 creator A5059625599 @default.
• W2934961572 creator A5062885345 @default.
• W2934961572 creator A5064294460 @default.
• W2934961572 creator A5064336169 @default.
• W2934961572 creator A5065556543 @default.
• W2934961572 creator A5076576740 @default.
• W2934961572 creator A5077473098 @default.
• W2934961572 creator A5081019088 @default.
• W2934961572 date "2019-05-02" @default.
• W2934961572 modified "2023-10-17" @default.
• W2934961572 title "Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL" @default.
• W2934961572 cites W1196637763 @default.
• W2934961572 cites W1512247569 @default.
• W2934961572 cites W1572743872 @default.
• W2934961572 cites W1590169868 @default.
• W2934961572 cites W1963522404 @default.
• W2934961572 cites W1966542058 @default.
• W2934961572 cites W1971518635 @default.
• W2934961572 cites W1971746066 @default.
• W2934961572 cites W2001850157 @default.
• W2934961572 cites W2016042196 @default.
• W2934961572 cites W2024216962 @default.
• W2934961572 cites W2042765435 @default.
• W2934961572 cites W2046562334 @default.
• W2934961572 cites W2047192675 @default.
• W2934961572 cites W2051549641 @default.
• W2934961572 cites W2052346599 @default.
• W2934961572 cites W2075736621 @default.
• W2934961572 cites W2095491662 @default.
• W2934961572 cites W2099570622 @default.
• W2934961572 cites W2112680373 @default.
• W2934961572 cites W2118796952 @default.
• W2934961572 cites W2119147717 @default.
• W2934961572 cites W2122792339 @default.
• W2934961572 cites W2129702476 @default.
• W2934961572 cites W2130338247 @default.
• W2934961572 cites W2135215267 @default.
• W2934961572 cites W2142099365 @default.
• W2934961572 cites W2142604595 @default.
• W2934961572 cites W2144491853 @default.
• W2934961572 cites W2145985838 @default.
• W2934961572 cites W2163533176 @default.
• W2934961572 cites W2165505341 @default.
• W2934961572 cites W2170513194 @default.
• W2934961572 cites W2219506342 @default.
• W2934961572 cites W2295348655 @default.
• W2934961572 cites W2296829012 @default.
• W2934961572 cites W2342423058 @default.
• W2934961572 cites W2343067948 @default.
• W2934961572 cites W2396328865 @default.
• W2934961572 cites W2509364267 @default.
• W2934961572 cites W2516709103 @default.
• W2934961572 cites W2530965063 @default.
• W2934961572 cites W2561662975 @default.
• W2934961572 cites W2580500393 @default.
• W2934961572 cites W2606654718 @default.
• W2934961572 cites W2735691291 @default.
• W2934961572 cites W2748623468 @default.
• W2934961572 cites W2773804840 @default.
• W2934961572 cites W2787301955 @default.
• W2934961572 cites W2787621143 @default.
• W2934961572 cites W2801641802 @default.
• W2934961572 cites W2804588678 @default.
• W2934961572 cites W2808493395 @default.
• W2934961572 cites W4249092807 @default.
• W2934961572 doi "https://doi.org/10.1172/jci.insight.122627" @default.
• W2934961572 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6538317" @default.
• W2934961572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30938714" @default.
• W2934961572 hasPublicationYear "2019" @default.
• W2934961572 type Work @default.
• W2934961572 sameAs 2934961572 @default.
• W2934961572 citedByCount "59" @default.
• W2934961572 countsByYear W29349615722019 @default.
• W2934961572 countsByYear W29349615722020 @default.
• W2934961572 countsByYear W29349615722021 @default.
• W2934961572 countsByYear W29349615722022 @default.
• W2934961572 countsByYear W29349615722023 @default.
• W2934961572 crossrefType "journal-article" @default.
• W2934961572 hasAuthorship W2934961572A5010957292 @default.
• W2934961572 hasAuthorship W2934961572A5011077747 @default.
• W2934961572 hasAuthorship W2934961572A5036831073 @default.
• W2934961572 hasAuthorship W2934961572A5040703931 @default.
• W2934961572 hasAuthorship W2934961572A5042888186 @default.
• W2934961572 hasAuthorship W2934961572A5044552886 @default.
• W2934961572 hasAuthorship W2934961572A5052659722 @default.
• W2934961572 hasAuthorship W2934961572A5059625599 @default.
• W2934961572 hasAuthorship W2934961572A5062885345 @default.
• W2934961572 hasAuthorship W2934961572A5064294460 @default.
• W2934961572 hasAuthorship W2934961572A5064336169 @default.
• W2934961572 hasAuthorship W2934961572A5065556543 @default.
• W2934961572 hasAuthorship W2934961572A5076576740 @default.

• next